tetano
Editor, Senior Moderator
Clin Kidney J
. 2021 Dec 20;15(3):560-563.
doi: 10.1093/ckj/sfab285. eCollection 2022 Mar.
De novo and relapsing necrotizing vasculitis after COVID-19 vaccination
Alexandre Fillon[SUP] 1 [/SUP], Benedicte Sautenet[SUP] 1 [/SUP], Christelle Barbet[SUP] 1 [/SUP], Léa Moret[SUP] 1 [/SUP], Eve Marie Thillard[SUP] 2 [/SUP], Annie Pierre Jonville-Béra[SUP] 3 [/SUP], Jean Michel Halimi[SUP] 1 [/SUP]
Affiliations
Abstract
We describe five cases of severe necrotizing vasculitis following the RNA-based vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), including four relapsing anti neutrophil cytoplasmic antibodies (ANCA) vasculitis, 27 days (1-60) after vaccination and one patient with quiescent chronic hepatitis B and de novo polyarteritis nodosa (PAN) 21 days after vaccination. Ten other cases were reported to the French national pharmacovigilance database: six patients with ANCA-associated vasculitis and four patients with PAN (first symptoms 19 days on average after vaccination). Five of these 10 patients developed kidney dysfunction. In conclusion, coronavirus disease 2019 (COVID-19) vaccines can be associated with de novo or recurrent ANCA vasculitis or PAN. Attention should be paid to patients with known ANCA vasculitis or patients with a history of hepatitis B infection.
Keywords: AKI; ANCA; crescentic glomerulonephritis; hepatitis B; immunology; kidney biopsy.
. 2021 Dec 20;15(3):560-563.
doi: 10.1093/ckj/sfab285. eCollection 2022 Mar.
De novo and relapsing necrotizing vasculitis after COVID-19 vaccination
Alexandre Fillon[SUP] 1 [/SUP], Benedicte Sautenet[SUP] 1 [/SUP], Christelle Barbet[SUP] 1 [/SUP], Léa Moret[SUP] 1 [/SUP], Eve Marie Thillard[SUP] 2 [/SUP], Annie Pierre Jonville-Béra[SUP] 3 [/SUP], Jean Michel Halimi[SUP] 1 [/SUP]
Affiliations
- PMID: 35211310
- PMCID: PMC8862065
- DOI: 10.1093/ckj/sfab285
Abstract
We describe five cases of severe necrotizing vasculitis following the RNA-based vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), including four relapsing anti neutrophil cytoplasmic antibodies (ANCA) vasculitis, 27 days (1-60) after vaccination and one patient with quiescent chronic hepatitis B and de novo polyarteritis nodosa (PAN) 21 days after vaccination. Ten other cases were reported to the French national pharmacovigilance database: six patients with ANCA-associated vasculitis and four patients with PAN (first symptoms 19 days on average after vaccination). Five of these 10 patients developed kidney dysfunction. In conclusion, coronavirus disease 2019 (COVID-19) vaccines can be associated with de novo or recurrent ANCA vasculitis or PAN. Attention should be paid to patients with known ANCA vasculitis or patients with a history of hepatitis B infection.
Keywords: AKI; ANCA; crescentic glomerulonephritis; hepatitis B; immunology; kidney biopsy.